IMF Medical Student Scholar for Health Equity in Myeloma Semaje Testamark Receives Prestigious 2023 ASH Abstract Achievement Award

Semaje Testamark, an IMF Medical Student Scholar, is among the recipients of the prestigious 2023 ASH Abstract Achievement Award, marking a significant achievement in health equity research. Collaborating with Dr. Manisha Bhutani of Atrium Health Levine Cancer Institute, Testamark's study on "Rural-Urban and Racial Trends in Survival of Patients with Multiple Myeloma" sheds light on disparities in healthcare access. Testamark's recognition underscores the IMF's commitment to nurturing diverse talent and fostering health equity research.

IMWG Conference Series: Making Sense of Treatment Webinar Coming Soon

Join us Thursday, December 14, 2023, at 11:00 a.m. PST/ 2:00 p.m. EST for the IMWG Conference Series, “Making Sense of Treatment.” Leading myeloma experts will discuss the latest myeloma research news from the 2023 American Society of Hematology (ASH) Annual Meeting and Expo. IMF Chairman of the Board and Chief Scientific Officer Dr. Brian G.M. Durie will moderate the discussion, with Drs. María V. Mateos (University of Salamanca—Salamanca, Spain) and Thomas Martin (University of California San Francisco—San Francisco, CA) serving as panelists. 

IMF Support Group Leaders Report Live During the 65th American Society of Hematology Annual Meeting and Exposition

Tune in as the IMF brings myeloma support group leaders and patients to the 65th annual meeting of the American Society of Hematology (ASH), “the world’s most comprehensive hematology event of the year.” The IMF thanks these leaders for their care and commitment in sharing their experiences with the global myeloma community. We encourage you to visit the website and follow these leaders for their unique perspectives.

Join IMF Chief Medical Officer Dr. Joseph Mikhael and the ASH Support Group Leaders Team LIVE at ASH 2023

IMF Chief Medical Officer Dr. Joseph Mikhael along with the ASH support group leader team go live to discuss key myeloma research takeaways from the 2023 American Society of Hematology meeting and exposition. This Facebook Live Event takes place on Monday, December 11, at 7:00 p.m. PST / 10:00 p.m. EST. Click the button below to visit the Facebook event page. Then click ‘Going’ to register.

Save the Date: Top Myeloma Research at ASH 2023 from a Patient Perspective

On Thursday, January 4, 2024, at 12:00 p.m. PST / 3:00 p.m. EST, IMF Chairman of the Board and Chief Scientific Officer Brian G.M. Durie will discuss important Top Myeloma Research and Key Takeaways from the 2023 American Society of Hematology (ASH) Conference, along with a panel of patient advocates including Jessie Daw, PhD, and Michael Tuohy. Together, they will sift through the data of 1,000+ myeloma-related abstracts from the ASH conference and present key points in approachable terms for everyday decision-making. 

Around the Web: Myeloma News

To keep you abreast of the most recent myeloma research findings, “The Myeloma Minute” features links to top myeloma content around the web. For this week, we encourage you to visit this article in Leukemia to learn about a study of 58 multiple myeloma patients receiving COVID-19 vaccines. These three press releases identify recent updates to myeloma therapies: This bispecific antibody trial in relapsed/refractory multiple myeloma patients yielded positive results but also a high number of adverse events and deaths; this Sarclisa® (isatuximab) phase III trial met its primary endpoint of progression-free survival in transplant-ineligible, newly diagnosed multiple myeloma patients; and finally, Japan granted marketing and manufacturing approval for Abecma (idecabtagene vicleucel) to treat relapsed or refractory multiple myeloma (RRMM).  

Also check out this wrap-up of top Myeloma News published in medical journals in November 2023. As always, we invite you to visit the IMF Newsroom for the most recent myeloma news.

#ASKDRDURIE | Dr. Durie's Weekly Web Video Series

What is the IMF’s iStopMM study?